Factors impacting HPV vaccination: Lessons for health care professionals

Expert Review of Vaccines

Volumn 13, Issue 8, 2014, Pages 1013-1026

  Hofstetter, Annika M ^a   Rosenthal, Susan L ^a  

^a Department of Pediatrics Division of Child and Adolescent Health Columbia University College of Physicians and Surg ^*  (United States)

Author keywords

Adolescent; Communication; Health care professional; HPV; Vaccination

Indexed keywords

WART VIRUS VACCINE;

AGE; ATTITUDE; CLINICAL TRIAL (TOPIC); COMFORT; FAMILY; GENDER; HEALTH BELIEF; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH EDUCATION; HUMAN; INTERPERSONAL COMMUNICATION; KNOWLEDGE; LICENSING; MEDICALLY UNDERSERVED; PAPILLOMAVIRUS INFECTION; PATIENT IDENTIFICATION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEXUAL HEALTH; SOCIAL DETERMINANTS OF HEALTH; VACCINATION; BEHAVIOR THERAPY; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; UTILIZATION;

BEHAVIOR THERAPY; HEALTH PERSONNEL; HEALTH POLICY; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; VACCINATION;

EID: 84904297284     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.933076     Document Type: Review

References (176)

1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30(Suppl 5):F12-23
2. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction - the first five years. Vaccine 2012; 30(Suppl 5):F139-48 •• This review study describes the successes and challenges of HPV vaccine introduction and HPV vaccination program implementation worldwide.
3. U.S. Department of Health and Human Services. Healthy people 2020. 2010. Available from: www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist. aspx?topicId=23 [Last accessed 24 February 2014]
4. Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011;11: 13
5. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121(3): 621-32
6. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364(5): 401-11
7. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365(17): 1576-85
8. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-2): 1-24
9. Hawkes D, Lea CE, Berryman MJ. Answering human papillomavirus vaccine concerns; a matter of science and time. Infect Agent Cancer 2013;8(1): 22
10. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23(5): 569-78
11. Sarojini NB, Srinivasan S, Madhavi Y, et al. The HPV vaccine: science, ethics and regulation. Econ Polit Wkly 2010;XLV(48): 27-34
12. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118(5): 2135-45
13. Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009; 44(1): 33-40
14. Food and Drug Administration. Product approval-prescribing information [package insert]. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck & Co, Inc: Food and Drug Administration. Available from: www.fda.gov/biologicsbloodvaccines/vaccines/ approvedproducts/ucm094042.htm [Last accessed 31 March 2014]
15. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59(20): 626-9
16. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59(20): 630-2
17. World Health Organization. Identifying needs for implementation and research. Report of the HPV vaccine delivery meeting; 17-19 April 2012; Geneva, Switzerland; 2012. Available from: http://apps.who.int/iris/bitstream/10665/ 76532/1/WHO-IVB-12.09-eng.pdf
18. Binagwaho A, Wagner CM, Gatera M, et al. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 2012;90(8): 623-8
19. LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011;89(11): 821-830B
20. Siegrist C. What are the optimal schedules human papilloma virus vaccines for adolescent girls? Paper presented at SAGE Meeting; Geneva, Switzerland; 2014. Available from: www.who.int/immunization/sage/meetings/2014/april/3-SAGE- April-HPV-Siegrist- Recommendations.pdf
21. Centers for Disease Control and Prevention. Progress toward implementation of human papillomavirus vaccination-the Americas, 2006-2010. MMWR Morb Mortal Wkly Rep 2011;60(40): 1382-4
22. Lazcano-Ponce E, Stanley M, Munoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014;32(6): 725-32 •• Two vaccine doses may provide adequate protection against HPV among adolescents. This may have significant public health and policy implications.
23. Lamontagne DS, Thiem VD, Huong VM, et al. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis 2013;208(8): 1325-34
24. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309(17): 1793-802
25. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60(50): 1705-8
26. Garland SM. The Australian experience with the human papillomavirus vaccine. Clin Ther 2014;36(1): 17-23
27. Public Health Agency of Canada. Publicly funded immunization programs in Canada - routine schedule for infants and children including special programs and catch-up programs (as of January 2014). 2014. Available from: www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php [Last accessed 3 March 2014]
28. Wilkinson E. Australia leads way on HPV vaccination in boys. Lancet Infect Dis 2012; 12(11): 831-2
29. Onder RF. HPV vaccine mandates: just say 'no' to the "great big public health experiment". Mo Med 2008;105(1): 8-11
30. Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? Ann Med 2013;45(2): 182-93
31. Haas M, Ashton T, Blum K, et al. Drugs, sex, money and power: an HPV vaccine case study. Health Policy 2009;92(2-3): 288-95
32. Stafford N. Germany reviews its policy on HPV vaccination for 12-17 year olds. BMJ 2009;338:b1692
33. Rondy M, van Lier A, van de Kassteele J, et al. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine 2010;28(9): 2070-5
34. Brady MT. Pediatricians can lay out evidence to allay fears over HPV vaccine. AAP News 2014;35: 9
35. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(Suppl 5):F123-38
36. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia - nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106(3):djt460 •• This population-based cohort study from Denmark found a significantly reduced risk of cervical lesions among females vaccinated against HPV compared to those who remained unvaccinated.
37. Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013;57(7): 929-34
38. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377(9783): 2085-92
39. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 2013;105(7): 469-74
40. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012;31(1): 109-13
41. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012;206(11): 1645-51
42. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208(3): 385-93
43. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11: 227
44. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010; 29(2): 95-101
45. Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep 2013;62(29): 591-5
46. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302(7): 750-7
47. Loughlin AM, Marchant CD, Adams W, et al. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine 2012; 30(50): 7253-9
48. The Tokyo Times. HPV vaccine seen differently by Japan and the U.S. 2013
49. Gilmour S, Kanda M, Kusumi E, et al. HPV vaccination programme in Japan. Lancet 2013;382(9894): 768
50. Lee SH. Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil. J Inorg Biochem 2012;117: 85-92
51. World Health Organization. Global Advisory Committee on Vaccine Safety: statement on the continued safety of HPV vaccination. 2014. Available from: www. who.int/vaccine-safety/committee/topics/hpv/GACVS-Statement-HPV-12-Mar-2014. pdf?ua=1 [Last accessed 22 May 2014]
52. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years - United States, 2012. MMWR Morb Mortal Wkly Rep 2013;62(34): 685-93
53. Dorleans F, Giambi C, Dematte L, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010;15: 47
54. National Services Scotland. HPV immunisation uptake statistics. 2013. Available from: https://isdscotland.scot.nhs. uk/Health-Topics/Child-Health/ Publications/2013-09-24/HPV-Report- September-2013.pdf?41376894713 [Last accessed 27 February 2014]
55. Annual HPV vaccine coverage in England : 2012-13. 2013. Available from: www.gov. uk/government/uploads/system/uploads/attachment-data/file/266207/HPV- AnnualDataTable2012-13-AT-acc5. pdf [Last accessed 27 February 2014]
56. Wilson SE, Harris T, Sethi P, et al. Coverage from Ontario, Canada's school-based HPV vaccine program: the first three years. Vaccine 2013;31(5): 757-62
57. Gilkey MB, Moss JL, McRee AL, Brewer NT. Do correlates of HPV vaccine initiation differ between adolescent boys and girls? Vaccine 2012;30(41): 5928-34
58. Hofstetter AM, Stockwell MS, Al-Husayni N, et al. HPV vaccination: are we initiating too late? Vaccine 2014;32(17): 1939-45
59. Wong CA, Taylor JA, Wright JA, et al. Missed opportunities for adolescent vaccination, 2006-2011. J Adolesc Health 2013;53(4): 492-7
60. Watson-Jones D, Baisley K, Ponsiano R, et al. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis 2012;206(5): 678-86
61. Zimet GD, Rosenthal SL. HPV vaccine and males: issues and challenges. Gynecol Oncol 2010;117:S26-31
62. Bastani R, Glenn BA, Tsui J, et al. Understanding suboptimal human papillomavirus vaccine uptake among ethnic minority girls. Cancer Epidemiol Biomarkers Prev 2011;20(7): 1463-72
63. Hoffman L, Okcu MF, Dreyer ZE, et al. Human papillomavirus vaccination in female pediatric cancer survivors. J Pediatr Adolesc Gynecol 2012;25(5): 305-7
64. Klosky JL, Russell KM, Canavera KE, et al. Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer. Cancer Prev Res (Phila) 2013;6(10): 1101-10
65. Widdice LE, Brown DR, Bernstein DI, et al. Prevalence of human papillomavirus infection in young women receiving the first quadrivalent vaccine dose. Arch Pediatr Adolesc Med 2012;166(8): 774-6
66. Dorell C, Yankey D, Jeyarajah J, et al. Delay and refusal of human papillomavirus vaccine for girls, national immunization survey-teen, 2010. Clin Pediatr (Phila) 2014;53(3): 261-9
67. Gelman A, Miller E, Schwarz EB, et al. Racial disparities in human papillomavirus vaccination: does access matter? J Adolesc Health 2013;53(6): 756-62
68. Tsui J, Gee GC, Rodriguez HP, et al. Exploring the role of neighborhood socio-demographic factors on HPV vaccine initiation among low-income, ethnic minority girls. J Immigr Minor Health 2013;15(4): 732-40
69. Bowyer HL, Forster AS, Marlow LA, Waller J. Predicting human papillomavirus vaccination behaviour among adolescent girls in England: results from a prospective survey. J Fam Plann Reprod Health Care 2014;40(1): 14-22
70. Sacks RJ, Copas AJ, Wilkinson DM, Robinson AJ. Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services. Sex Transm Infect 2014;90(4): 315-21
71. Fernandez ME, Allen JD, Mistry R, Kahn JA. Integrating clinical, community, and policy perspectives on human papillomavirus vaccination. Annu Rev Public Health 2010;31: 235-52
72. Madhivanan P, Li T, Srinivas V, et al. Human papillomavirus vaccine acceptability among parents of adolescent girls: obstacles and challenges in Mysore, India. Prev Med 2014;64C: 69-74
73. Marek E, Dergez T, Kricskovics A, et al. Difficulties in the prevention of cervical cancer: adults' attitudes towards HPV vaccination 3 years after introducing the vaccine in Hungary. Vaccine 2011;29(32): 5122-9
74. Hendry M, Lewis R, Clements A, et al. "HPV? Never heard of it!": a systematic review of girls' and parents' information needs, views and preferences about human papillomavirus vaccination. Vaccine 2013; 31(45): 5152-67
75. Reiter PL, Gilkey MB, Brewer NT. HPV vaccination among adolescent males: results from the National Immunization Survey-Teen. Vaccine 2013;31(26): 2816-21 • This study is among the first to describe predictors of HPV vaccine uptake among male adolescents.
76. Liddon N, Michael SL, Dittus P, Markowitz LE. Maternal underestimation of child's sexual experience: suggested implications for HPV vaccine uptake at recommended ages. J Adolesc Health 2013; 53(5): 674-6
77. Mayhew A, Mullins TL, Ding L, et al. Risk Perceptions and Subsequent Sexual Behaviors After HPV Vaccination in Adolescents. Pediatrics 2014;133(3): 404-11
78. Bednarczyk RA, Davis R, Ault K, et al. Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics 2012;130(5): 798-805
79. Darden PM, Thompson DM, Roberts JR, et al. Reasons for not vaccinating adolescents: National immunization survey of teens, 2008-2010. Pediatrics 2013; 131(4): 645-51
80. Reimer RA, Houlihan AE, Gerrard M, et al. Ethnic differences in predictors of HPV vaccination: comparisons of predictors for Latina and non-Latina White women. J Sex Res 2013;50(8): 748-56
81. Joseph NP, Clark JA, Bauchner H, et al. Knowledge, attitudes, and beliefs regarding HPV vaccination: ethnic and cultural differences between African-American and Haitian immigrant women. Womens Health Issues 2012;22(6):e571-9
82. Wilson R, Brown DR, Boothe MA, Harris CE. Knowledge and acceptability of the HPV vaccine among ethnically diverse black women. J Immigr Minor Health 2013;15(4): 747-57
83. Marlow LA, Wardle J, Forster AS, Waller J. Ethnic differences in human papillomavirus awareness and vaccine acceptability. J Epidemiol Community Health 2009; 63(12): 1010-15
84. Chow SN, Soon R, Park JS, et al. Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccination amongst urban Asian mothers and physicians. Vaccine 2010;28(22): 3809-17
85. Boyce T, Holmes A. Addressing health inequalities in the delivery of the human papillomavirus vaccination programme: examining the role of the school nurse. PLoS One 2012;7(9):e43416
86. Pitts M, Smith A, Croy S, et al. Singaporean women's knowledge of human papillomavirus (HPV) and attitudes toward HPV vaccination. Women Health 2009; 49(4): 334-51
87. Dinh TA, Rosenthal SL, Doan ED, et al. Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J Adolesc Health 2007;40(6): 559-63
88. Rosenthal SL, Weiss TW, Zimet GD, et al. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine 2011; 29(5): 890-5
89. Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey. Am J Public Health 2012;103(1): 164-9
90. Lau M, Lin H, Flores G. Factors associated with human papillomavirus vaccine-series initiation and healthcare provider recommendation in US adolescent females: 2007 National Survey of Children's Health. Vaccine 2012;30(20): 3112-18
91. Kester LM, Zimet GD, Fortenberry JD, et al. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J 2013;17(5): 879-85
92. Donahue KL, Stupiansky NW, Alexander AB, Zimet GD. Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons. Vaccine 2014. [Epub ahead of print]
93. Tan J, Farrell L, Allen DG. The attitudes of Australian gynaecologists to HPV vaccination: an ASCCP survey. Aust N Z J Obstet Gynaecol 2010;50(5): 472-7
94. Hughes CC, Jones AL, Feemster KA, Fiks AG. HPV vaccine decision making in pediatric primary care: a semi-structured interview study. BMC Pediatr 2011;11: 74
95. Wong LP. Physicians' experiences with HPV vaccine delivery: evidence from developing country with multiethnic populations. Vaccine 2009;27(10): 1622-7
96. Kahn JA, Cooper HP, Vadaparampil ST, et al. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians. Cancer Epidemiol Biomarkers Prev 2009;18(8): 2325-32
97. Weiss TW, Zimet GD, Rosenthal SL, et al. Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females. J Adolesc Health 2010; 47(1): 3-11
98. Allison MA, Dunne EF, Markowitz LE, et al. HPV vaccination of boys in primary care practices. Acad Pediatr 2013;13(5): 466-74 • This is one of the first studies of health care professionals to focus on HPV vaccination of males after the Advisory Committee on Immunization Practices permissive recommendation was issued in the USA.
99. Post RE, Carek PJ, Mainous AG 3rd, et al. Factors affecting HPV vaccine use among recent family medicine residency graduates. Family Med 2013;45(2): 90-4
100. Vadaparampil ST, Kahn JA, Salmon D, et al. Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine 2011;29(47): 8634-41
101. Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics 2010;126(3): 425-33
102. Vadaparampil ST, Malo TL, Kahn JA, et al. Physicians' human papillomavirus vaccine recommendations, 2009 and 2011. Am J Prev Med 2014;46(1): 80-4
103. Quinn GP, Murphy D, Malo TL, et al. A national survey about human papillomavirus vaccination: what we didn't ask, but physicians wanted us to know. J Pediatr Adolesc Gynecol 2012;25(4): 254-8
104. Holder NA, Katzenellenbogen R, Middleman AB. Human papillomavirus vaccines: factors that affect vaccine knowledge and delivery. J Adolesc Health 2013;53(3): 423-5
105. McCave EL. Influential factors in HPV vaccination uptake among providers in four states. J Community Health 2010;35(6): 645-52
106. Maheux B, Haley N, Rivard M, Gervais A. STD risk assessment and risk-reduction counseling by recently trained family physicians. Acad Med 1995;70(8): 726-8
107. Vadaparampil ST, Murphy D, Rodriguez M, et al. Qualitative responses to a national physician survey on HPV vaccination. Vaccine 2013;31(18): 2267-72
108. Wiehe SE, Rosenman MB, Wang J, et al. Chlamydia screening among young women: individual - and provider-level differences in testing. Pediatrics 2011;127(2):e336-44
109. Perkins RB, Brogly SB, Adams WG, Freund KM. Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study. J Womens Health (Larchmt) 2012;21(8): 813-20
110. Dinas K, Nasioutziki M, Arvanitidou O, et al. Awareness of human papillomavirus infection, testing and vaccination in midwives and midwifery students in Greece. J Obstet Gynaecol 2009;29(6): 542-6
111. Urasa M, Darj E. Knowledge of cervical cancer and screening practices of nurses at a regional hospital in Tanzania. Afr Health Sci 2011;11(1): 48-57
112. Songthap A, Pitisuttithum P, Kaewkungwal J, et al. Knowledge, attitudes, and acceptability of a human papillomavirus vaccine among healthcare providers. Southeast Asian J Trop Med Public Health 2009;40(5): 1048-56
113. Saraiya M, Rosser JI, Cooper CP. Cancers that U.S. physicians believe the HPV vaccine prevents: findings from a physician survey, 2009. J Womens Health (Larchmt) 2012;21(2): 111-17
114. de Carvalho NS, Teixeira LM, Pradel EM, et al. Vaccinating against HPV: physicians' and medical students' point of view. Vaccine 2009;27(20): 2637-40
115. Hopkins TG, Wood NJ, West RM, Darling JC. UK health professionals' attitudes and knowledge regarding human papillomavirus (HPV) vaccination: a West Yorkshire Study. J Paediatr Child Health 2009;45(11): 652-5
116. Goff SL, Mazor KM, Gagne SJ, et al. Vaccine counseling: a content analysis of patient-physician discussions regarding human papilloma virus vaccine. Vaccine 2011;29(43): 7343-9
117. Kepka D, Berkowitz Z, Yabroff KR, et al. Human papillomavirus vaccine practices in the USA: do primary care providers use sexual history and cervical cancer screening results to make HPV vaccine recommendations? Sex Transm Infect 2012; 88(6): 433-5
118. Tafuri S, Martinelli D, Vece MM, et al. Communication skills in HPV prevention: an audit among Italian healthcare workers. Vaccine 2010;28(34): 5609-13
119. Rand CM, Schaffer SJ, Humiston SG, et al. Patient-provider communication and human papillomavirus vaccine acceptance. Clin Pediatr (Phila) 2010;50(2): 106-13
120. Centers for Disease Control and Prevention. Tips and time-savers for talking with parents about HPV vaccine. Available from: www.cdc.gov/vaccines/ who/teens/for-hcptipsheet- hpv.pdf [Last accessed 18 March 2014]
121. Leader AE, Weiner JL, Kelly BJ, et al. Effects of information framing on human papillomavirus vaccination. J Womens Health (Larchmt) 2009;18(2): 225-33
122. Zimet GD, Perkins SM, Sturm LA, et al. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 2005;37(3): 179-86
123. Rosenthal SL, Rupp R, Zimet GD, et al. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. J Adolesc Health 2008;43(3): 239-45
124. Juraskova I, O'Brien M, Mullan B, et al. HPV vaccination and the effect of information framing on intentions and behaviour: an application of the theory of planned behaviour and moral norm. Int J Behav Med 2011;19(4): 518-25
125. McRee AL, Reiter PL, Chantala K, Brewer NT. Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability? Cancer Epidemiol Biomarkers Prev 2010; 19(8): 1937-44
126. Fu LY, Bonhomme LA, Cooper SC, et al. Educational interventions to increase HPV vaccination acceptance: a systematic review. Vaccine 2014;32(17): 1901-20 • This systematic review found that educational interventions targeting adolescents, young adults and parents, including the use of different message framing strategies, have been largely unsuccessful in increasing HPV vaccine uptake.
127. Van 't Riet J, Cox AD, Cox D, et al. Does perceived risk influence the effects of message framing? A new investigation of a widely held notion. Psychol Health 2014; 29(8): 933-49
128. Rand CM, Shone LP, Albertin C, et al. National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med 2007;161(3): 252-9
129. Alexander AB, Stupiansky NW, Ott MA, et al. Parent-son decision-making about human papillomavirus vaccination: a qualitative analysis. BMC Pediatr 2012;12: 192
130. Rand CM, Humiston SG, Schaffer SJ, et al. Parent and adolescent perspectives about adolescent vaccine delivery: practical considerations for vaccine communication. Vaccine 2011;29(44): 7651-8
131. Gowda C, Schaffer SE, Dombkowski KJ, Dempsey AF. Understanding attitudes toward adolescent vaccination and the decision-making dynamic among adolescents, parents and providers. BMC Public Health 2012;12: 509
132. Alexander AB, Stupiansky NW, Ott MA, et al. What parents and their adolescent sons suggest for male HPV vaccine messaging. Health Psychol 2014;33(5): 448-56
133. The Community Guide. Increasing appropriate vaccination. 2014. Available from: www.thecommunityguide.org/vaccines/index.html [Last accessed 21 May 2014]
134. Stockwell MS, Fiks AG. Utilizing health information technology to improve vaccine communication and coverage. Hum Vaccin Immunother 2013;9(8): 1802-11
135. Vawdrey DK, Natarajan K, Kanter AS, et al. Informatics lessons from using a novel immunization information system. Stud Health Technol Inform 2013;192: 589-93
136. Fiks AG, Grundmeier RW, Mayne S, et al. Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics 2013;131(6): 1114-24 • This study found that an electronic health record-based intervention targeting clinicians and automated educational reminder telephone calls targeting families improved HPV vaccination coverage. The former was particularly beneficial for initiating HPV vaccination, whereas the latter was more effective in promoting completion of the three-dose series.
137. Moss JL, Reiter PL, Dayton A, Brewer NT. Increasing adolescent immunization by webinar: a brief provider intervention at federally qualified health centers. Vaccine 2012;30(33): 4960-3
138. Robotin M, Patton Y, George J. Getting it right: the impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers. Int J Gen Med 2013;6: 115-22
139. Sheinfeld Gorin SN, Glenn BA, Perkins RB. The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. Adv Ther 2011;28(8): 615-39
140. Rosberger Z, Krawczyk A, Stephenson E, Lau S. HPV vaccine education: enhancing knowledge and attitudes of community counselors and educators. J Cancer Educ 2013. [Epub ahead of print]
141. Cox DS, Cox AD, Sturm L, Zimet G. Behavioral interventions to increase HPV vaccination acceptability among mothers of young girls. Health Psychol 2010;29(1): 29-39
142. Chapman E, Venkat P, Ko E, et al. Use of multimedia as an educational tool to improve human papillomavirus vaccine acceptability - a pilot study. Gynecol Oncol 2010;118(2): 103-7
143. Mayne S, Karavite D, Grundmeier RW, et al. The implementation and acceptability of an HPV vaccination decision support system directed at both clinicians and families. AMIA Annu Symp Proc 2012;2012: 616-24
144. Suh CA, Saville A, Daley MF, et al. Effectiveness and net cost of reminder/recall for adolescent immunizations. Pediatrics 2012;129(6):e1437-45
145. Kharbanda EO, Stockwell MS, Fox HW, et al. Text message reminders to promote human papillomavirus vaccination. Vaccine 2011;29(14): 2537-41
146. Matheson EC, Derouin A, Gagliano M, et al. Increasing HPV vaccination series completion rates via text message reminders. J Pediatr Health Care 2013. [Epub ahead of print]
147. Irigoyen MM, Findley S, Wang D, et al. Challenges and successes of immunization registry reminders at inner-city practices. Ambul Pediatr 2006;6(2): 100-4
148. LeBaron CW, Starnes DM, Rask KJ. The impact of reminder-recall interventions on low vaccination coverage in an inner-city population. Arch Pediatr Adolesc Med 2004;158(3): 255-61
149. Hofstetter AM, Vargas CY, Kennedy A, et al. Parental and provider preferences and concerns regarding text message reminder/recall for early childhood vaccinations. Prev Med 2013;57(2): 75-80
150. Gargano LM, Thacker N, Choudhury P, et al. Attitudes of pediatricians and primary health center physicians in India concerning routine immunization, barriers to vaccination, and missed opportunities to vaccinate. Pediatr Infect Dis J 2012;31(2): e37-42
151. Society for Adolescent Health and Medicine. English A, Ford CA, Kahn JA, et al. Adolescent consent for vaccination: a position paper of the Society for Adolescent Health and Medicine. J Adolesc Health 2013;53(4): 550-3
152. Szilagyi PG, Rand CM, McLaurin J, et al. Delivering adolescent vaccinations in the medical home: a new era? Pediatrics 2008; 121(Suppl 1):S15-24
153. World Health Organization. Making health services adolescent friendly: developing national quality standards for adolescent-friendly health services. 2012. Available from: www.who.int/maternal-child-adolescent/documents/ adolescent-friendly-services/en/index.html [Last accessed 19 January 2013]
154. Sara Test F, Caskey R, Rankin KM. The relationship between receiving care within a medical home and HPV vaccine receipt for adolescent girls: results of the 2007 National Survey of Children's Health. Matern Child Health J 2012;17(2): 274-81
155. Downs LS Jr, Scarinci I, Einstein MH, et al. Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol 2010;117(3): 486-90
156. Pandolfi E, Carloni E, Marino MG, et al. Immunization coverage and timeliness of vaccination in Italian children with chronic diseases. Vaccine 2012;30(34): 5172-8
157. Raddish M, Goldmann DA, Kaplan LC, Perrin JM. The immunization status of children with spina bifida. Am J Dis Child 1993;147(8): 849-53
158. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006;101(8): 1834-40
159. Tillmann BU, Tillmann HC, Heininger U, et al. Acceptance and timeliness of standard vaccination in children with chronic neurological deficits in north-western Switzerland. Eur J Pediatr 2005;164(5): 320-5
160. Basco WT Jr, Recknor JC, Darden PM. Who needs an immunization in a pediatric subspecialty clinic? Arch Pediatr Adolesc Med 1996;150(5): 508-11
161. Nakamura MM, Lee GM. Influenza vaccination in adolescents with high-risk conditions. Pediatrics 2008;122(5): 920-8
162. Daley MF, Beaty BL, Barrow J, et al. Missed opportunities for influenza vaccination in children with chronic medical conditions. Arch Pediatr Adolesc Med 2005; 159(10): 986-91
163. Klosky JL, Foster RH, Hodges J, et al. Human papillomavirus vaccination and the primary prevention of cancer: implications for survivors of childhood cancer. Stud Health Technol Inform 2012;172: 33-42
164. Malouf MA, Hopkins PM, Singleton L, et al. Sexual health issues after lung transplantation: importance of cervical screening. J Heart Lung Transplant 2004; 23(7): 894-7
165. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus 2010;19(13): 1485-91
166. de Araujo MR, Rubira-Bullen IR, Santos CF, et al. High prevalence of oral human papillomavirus infection in Fanconi's anemia patients. Oral Dis 2011; 17(6): 572-6
167. Seale H, Trung L, Mackie FE, et al. A qualitative study investigating knowledge and attitudes regarding human papillomavirus (HPV) and the HPV vaccine among parents of immunosuppressed children. Vaccine 2012;30(49): 7027-31 • This study is among the first to examine factors influencing HPV vaccination of adolescents with immunocompromising conditions.
168. Britto MT, Garrett JM, Dugliss MA, et al. Risky behavior in teens with cystic fibrosis or sickle cell disease: a multicenter study. Pediatrics 1998;101(2): 250-6
169. Suris JC, Michaud PA, Akre C, Sawyer SM. Health risk behaviors in adolescents with chronic conditions. Pediatrics 2008;122(5): e1113-18
170. Crawford NW, Bines JE, Royle J, Buttery JP. Optimizing immunization in pediatric special risk groups. Expert Rev Vaccines 2011;10(2): 175-86
171. Carroll G, Massarelli E, Opzoomer A, et al. Adolescents with chronic disease. Are they receiving comprehensive health care? J Adolesc Health Care 1983;4(4): 261-5
172. De Vincenzo R, Ricci C, Conte C, Scambia G. HPV vaccine cross-protection: highlights on additional clinical benefit. Gynecol Oncol 2013;130(3): 642-51
173. Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 2014; 32(14): 1595-601
174. Smith MA, Canfell K. Testing previous model predictions against new data on human papillomavirus vaccination program outcomes. BMC Res Notes 2014;7(1): 109
175. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): final minutes of the meeting held on 17-20 February 2014. 2014. Available from: www.ema.europa.eu/docs/en-GB/document-library/Minutes/2014/03/ WC500163635.pdf [Last accessed 21 May 2014]
176. Hofstetter AM, Rosenthal SL. Health care professional communication about STI vaccines with adolescents and parents. Vaccine 2014;32(14): 1616-23